同步放化疗联合尼妥珠单抗治疗晚期鼻咽癌的临床效果  

Clinical Effect of Simultaneous Chemoradiotherapy Combined with Nituzumab in the Treatment of Advanced Nasopharyngeal Carcinoma

作　　者：龚永谦[1] 刘利军[1] 罗兴谷 廖晴云 江青山[1] 向政 Gong Yongqian;Liu Lijun;Luo Xinggu;Liao Qingyun;Jiang Qingshan;Xiang Zheng(Department of Otolaryngology,the First Affiliated Hospital of University of South China,Hengyang 421001,Hunan Province,China)

机构地区：[1]南华大学附属第一医院耳鼻咽喉科,湖南衡阳421001

出　　处：《中外医药研究》2023年第9期6-8,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

基　　金：湖南省科技计划项目(编号:2020SK51804);湖南省自然科学基金项目(编号:2021JJ70117);湖南省卫生健康委科研计划项目(编号:D202307017081)。

摘　　要：目的:探析对晚期鼻咽癌患者行同步放化疗联合尼妥珠单治疗的临床效果。方法:选取2022年1月—2023年2月南华大学附属第一医院收治的鼻咽癌晚期(M分期)患者40例作为观察对象,按照随机数字表法分为对照组和观察组,各20例。对照组行同步放化疗,观察组在同步放化疗基础上联合尼妥珠单抗治疗。比较两组生化指标[谷丙转氨酶(ALT)、白细胞(WBC)、血小板(PLT)]、不良反应发生率、临床疗效。结果:治疗后,观察组ALT高于对照组,WBC、PLT低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组治疗有效率高于对照组,差异有统计学意义(P=0.047)。结论:对鼻咽癌晚期患者行同步放化疗联合尼妥珠单抗治疗效果确切,可改善患者生化指标,安全性较高。Objective:To explore the clinical effect of simultaneous chemoradiotherapy combined with nituzumab in the treatment of advanced nasopharyngeal carcinoma.Methods:40 patients with advanced nasopharyngeal carcinoma(M stage)admitted to the First Affiliated Hospital of University of South China from January 2022 to February 2023 were selected as observation objects,and were divided into control group and observation group according to random number table method,with 20 cases in each group.The control group received concurrent chemoradiation and chemotherapy,and the observation group was combined with nituzumab on the basis of simultaneous chemoradiation and chemotherapy.The biochemical indexes(ALT,WBC,PLT),incidence of adverse reactions and clinical efficacy of the two groups were compared.Results:After treatment,ALT in observation group was higher than control group,WBC and PLT were lower than control group,the difference was statistically significant(P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05);The effective rate of treatment in the observation group was higher than that in the control group,the difference was statistically significant(P=0.047).Conclusion:Simultaneous chemoradiotherapy combined with nituzumab is effective in the treatment of advanced nasopharyngeal carcinoma,which can improve the biochemical indexes of patients with high safety.

关 键 词：同步放化疗 尼妥珠单抗 鼻咽癌 

分 类 号：R73[医药卫生—肿瘤]